Zoetis (ZTS) PT Set at $85.00 by Cantor Fitzgerald
Several other equities research analysts have also recently commented on ZTS. BidaskClub cut Zoetis from a strong-buy rating to a buy rating in a research note on Wednesday, September 20th. Zacks Investment Research raised Zoetis from a hold rating to a buy rating and set a $71.00 price target for the company in a research note on Thursday, October 12th. Stifel Nicolaus reissued a buy rating and issued a $65.00 price target on shares of Zoetis in a research note on Tuesday, October 24th. BMO Capital Markets set a $65.00 price target on Zoetis and gave the company a hold rating in a research note on Wednesday, October 25th. Finally, Morgan Stanley boosted their price target on Zoetis from $61.00 to $70.00 and gave the company an equal weight rating in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $71.94.
Shares of Zoetis (NYSE:ZTS) opened at $75.39 on Thursday. The company has a market capitalization of $36,736.64, a P/E ratio of 34.58, a P/E/G ratio of 1.90 and a beta of 1.06. Zoetis has a 12 month low of $52.00 and a 12 month high of $75.69. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be issued a $0.126 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s payout ratio is 22.11%.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in Zoetis in the 3rd quarter worth approximately $114,000. Harfst & Associates Inc. lifted its holdings in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. lifted its holdings in Zoetis by 86.5% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after purchasing an additional 1,040 shares during the last quarter. Hedge funds and other institutional investors own 93.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zoetis (ZTS) PT Set at $85.00 by Cantor Fitzgerald” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/zoetis-zts-pt-set-at-85-00-by-cantor-fitzgerald/1806876.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.